问题 › 我们的销售周期太长 › HealthTech与数字健康
周期长通常是因为运营方未能向CFO证明风险分担在测量窗口后仍能维持，而非销售未能解释产品。 数字健康公司面临更难的结构性问题：结果风险的签署速度快于公司判断自身能否承担的速度——12个月测量窗口对11个月销售周期。因此任何可信方案都必须同时处理风险收入分成与参与率，而这正是大多数内部分析停止的地方，因为两者存在于不同系统。
周期长通常是因为运营方未能向CFO证明风险分担在测量窗口后仍能维持，而非销售未能解释产品。 数字健康公司面临更难的结构性问题：结果风险的签署速度快于公司判断自身能否承担的速度——12个月测量窗口对11个月销售周期。因此任何可信方案都必须同时处理风险收入分成与参与率，而这正是大多数内部分析停止的地方，因为两者存在于不同系统。
周期长很少是因为对平台的兴趣停滞。停滞通常发生在运营方必须仅用已收集的参与率和归因结果数据，向未参与会议的CFO或CEO证明风险收入分成是否合理这一阶段。
这重新定义了解决方式。缩短周期主要在于给内部支持者提供材料，用以在PMPM、参与率下降导致毛利率压缩的风险，以及归因结果与持续客户流失的对比上赢得内部论证。
另一个常见原因是向临床或运营负责人销售，而他们无权批准风险分成。这不会明显延长可见周期，而是增加隐藏的尾部周期，因为交易需等待CFO审核。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 交易在试点后持续停滞，因为参与率数据必须转化为风险分成模型
✓ 同一机会的预测日期反复推迟，同时CFO在审核PMPM和毛利率预测
✓ 丢单中的主要竞争对手是不做决定，表现为已注册会员基础上的持续客户流失
通常会让情况更糟的做法。 增加跟进活动，这会加大支持者的压力，却未提供归因结果或PMPM的新材料供其带给CFO。
It is for you if you run or finance a digital health company and deals consistently stall at the same stage. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家数字健康公司. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Vantabridge Health, a sample company profile used for testing rather than a customer — $62M ARR, 340,000 enrolled members.
Excerpt from a real Percision run · Competitive Positioning · sample company profile
The move. Monetize the largest three-condition outcomes dataset to subsidize outcomes risk and generate 13% growth without increasing at-risk share.
The leak it closes. Reduces dependence on 38% at-risk PMPM revenue by adding non-at-risk, high-margin revenue stream
The assumption it rests on. State privacy laws do not mandate patient-level consent for de-identified data before 2029 — the engine put the probability at 0.7.
| Investment required | $1.8–2.4M over 18 months |
| Expected return | 2.3–3.8× on $2.1M midpoint investment within 36 months |
| Revenue, year 1 | $0.8–1.2M ARR (3–4 deals) |
| Revenue, year 2 | $2.4–3.6M ARR (9–12 deals) |
| Revenue, year 3 | $4.2–6.8M ARR (15–20 deals) |
| Exit criteria | Kill move if fewer than 2 deals ≥$150k ACV close by Month 12 OR if any state privacy statute requiring patient-level consent for de-identified data is enacted before Month 18; reallocate remaining budget to Clinical Coaching Capacity Marketplace node |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Go-to-Market与商业策略, one of 29 engagements the platform runs. For 数字健康公司 it works through at-risk revenue share, engagement rate, gross margin and logo churn, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
找出交易停滞最久的阶段，分析买方在那里必须完成什么。这几乎总是内部审批，解决方式是提供材料而非说服。
这只会压缩最后一步，对周期中更早的停滞点无效，而时间正是消耗在这些停滞上。它还会让买方学会等待会得到奖励。
不一定，如果交易规模和成交率能够支撑。它成为问题的前提是周期长于现金周转允许的范围，这属于融资约束而非销售问题。
Materially, yes. Outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are at-risk revenue share, engagement rate, gross margin, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on at-risk revenue share and engagement rate. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית